Bioverativ

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Bioverativ and buy or sell other stocks, ETFs, and their options commission-free!

About BIVV

Bioverativ, Inc. is a global biopharmaceutical company, focused on discovery, research, development and commercialization of therapies for the treatment of blood diseases including hemophilia. The company is headquartered in Cambridge, MA. 

CEO
John G. Cox, MBA
CEOJohn G. Cox, MBA
Employees
Employees
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2017
Founded2017
Employees
Employees

BIVV Key Statistics

Market cap
11.36B
Market cap11.36B
Price-Earnings ratio
32.01
Price-Earnings ratio32.01
Dividend yield
Dividend yield
Average volume
3.24M
Average volume3.24M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$105.01
52 Week high$105.01
52 Week low
$48.14
52 Week low$48.14

Stock Snapshot

The current Bioverativ(BIVV) stock price is $104.65, with a market capitalization of 11.36B. The stock trades at a price-to-earnings (P/E) ratio of 32.01.

Bioverativ(BIVV) stock opened on 2026-04-05 at —. The price climbed to — and dipped to —.

The Bioverativ(BIVV)'s current trading volume is 0, compared to an average daily volume of 3.24M.

In the last year, Bioverativ(BIVV) shares hit a 52-week high of $105.01 and a 52-week low of $48.14.

In the last year, Bioverativ(BIVV) shares hit a 52-week high of $105.01 and a 52-week low of $48.14.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.